InvestorsHub Logo
Followers 368
Posts 5763
Boards Moderated 0
Alias Born 07/18/2009

Re: None

Monday, 12/27/2021 3:56:17 PM

Monday, December 27, 2021 3:56:17 PM

Post# of 118382
We should be gerring very efffing close by now---


Between July 16, 2021 and November 4, 2021 Regen Biopharma, Inc. (the “Company”) has satisfied $967,830 of principal indebtedness on convertible notes payable and $539,392 in fees, penalties and interest accrued but unpaid on convertible notes payable through the issuance of 706,451,543 of the Company’s common shares, 23,720,548 of the Company’s Series A Preferred shares and payment to noteholders of $218,529 in cash. As of June 30, 2021 the Company had convertible notes payable with an outstanding principal balance of $2,364,075 and as of November 4, 2021 the Company had convertible notes payable with an outstanding principal balance of $1,396,245.